These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 16140454

  • 21. Follicular fluid vascular endothelial growth factor concentrations are increased during GnRH antagonist/FSH ovarian stimulation cycles.
    Ferrari B, Pezzuto A, Barusi L, Coppola F.
    Eur J Obstet Gynecol Reprod Biol; 2006 Jan 01; 124(1):70-6. PubMed ID: 16183188
    [Abstract] [Full Text] [Related]

  • 22. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
    Jabłońska E, Kiersnowska-Rogowska B, Rogowski F, Parfieńczyk A, Puzewska W, Bukin M.
    Rocz Akad Med Bialymst; 2005 Jan 01; 50():204-7. PubMed ID: 16358967
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Seasonal changes of proapoptotic soluble Fas ligand level in allergic rhinitis combined with asthma.
    Mezei G, Lévay M, Sepler Z, Héninger E, Kozma GT, Cserháti E.
    Pediatr Allergy Immunol; 2006 Sep 01; 17(6):444-9. PubMed ID: 16925690
    [Abstract] [Full Text] [Related]

  • 26. Prognostic significance of soluble fas and soluble fas ligand in serum of patients with complete hydatidiform moles.
    Soni S, Rath G, Deval R, Salhan S, Mishra AK, Saxena S.
    Am J Reprod Immunol; 2011 Sep 01; 66(3):230-6. PubMed ID: 21385271
    [Abstract] [Full Text] [Related]

  • 27. sFas and sFas ligand and pediatric sepsis-induced multiple organ failure syndrome.
    Doughty L, Clark RS, Kaplan SS, Sasser H, Carcillo J.
    Pediatr Res; 2002 Dec 01; 52(6):922-7. PubMed ID: 12438671
    [Abstract] [Full Text] [Related]

  • 28. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
    Fu Y, Xiao QM, Wang T, Chen XH, Ai YH.
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov 01; 18(11):691-4. PubMed ID: 17092425
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
    Murakami M, Sasaki T, Miyata H, Yamasaki S, Kuwahara K, Chayama K.
    Oncol Rep; 2004 Jun 01; 11(6):1183-6. PubMed ID: 15138553
    [Abstract] [Full Text] [Related]

  • 31. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN, Engmann L, DiLuigi A, Maier D, Nulsen J, Benadiva C.
    Fertil Steril; 2009 Jul 01; 92(1):226-30. PubMed ID: 18675961
    [Abstract] [Full Text] [Related]

  • 32. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
    Tinazzi E, Puccetti A, Gerli R, Rigo A, Migliorini P, Simeoni S, Beri R, Dolcino M, Martinelli N, Corrocher R, Lunardi C.
    Int Immunol; 2009 Mar 01; 21(3):237-43. PubMed ID: 19181929
    [Abstract] [Full Text] [Related]

  • 33. Significance of Fas and Fas ligand in tuberculous lymphadenitis.
    Mustafa T, Mogga SJ, Mfinanga SG, Mørkve O, Sviland L.
    Immunology; 2005 Feb 01; 114(2):255-62. PubMed ID: 15667570
    [Abstract] [Full Text] [Related]

  • 34. Regulated upon activation, normal T cell expressed and secreted (RANTES) and monocyte chemotactic protein 1 in follicular fluid accumulate differentially in patients with and without endometriosis undergoing in vitro fertilization.
    Xu H, Schultze-Mosgau A, Agic A, Diedrich K, Taylor RN, Hornung D.
    Fertil Steril; 2006 Dec 01; 86(6):1616-20. PubMed ID: 16997300
    [Abstract] [Full Text] [Related]

  • 35. [Levels and clinic significance of serum soluble Fas and soluble Fas ligand in coal workers' pneumoconiosis].
    Yuan BJ, Liu ZZ, Ding XR, Zou JM.
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 Feb 01; 24(2):96-8. PubMed ID: 16600114
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Gonadotropin-releasing hormone antagonists increase follicular fluid insulin-like growth factor-I and vascular endothelial growth factor during ovarian stimulation cycles.
    Ferrari B, Pezzuto A, Barusi L, Coppola F.
    Gynecol Endocrinol; 2006 Jun 01; 22(6):289-96. PubMed ID: 16785153
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Follicular fluid levels of anti-Mullerian hormone as a predictor of oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome.
    Mashiach R, Amit A, Hasson J, Amzalzg S, Almog B, Ben-Yosef D, Lessing JB, Limor R, Azem F.
    Fertil Steril; 2010 May 01; 93(7):2299-302. PubMed ID: 19261276
    [Abstract] [Full Text] [Related]

  • 40. E-selectin, resistin and reactive oxygen species levels in GnRH -agonist and -antagonist protocols in IVF/ICSI: a prospective cohort study.
    Siristatidis C, Askoxylaki M, Varounis C, Kassanos D, Chrelias C.
    J Assist Reprod Genet; 2015 Jun 01; 32(6):959-67. PubMed ID: 25925352
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.